FAQ: How is MASH severity staged? What would an ideal MASH NIT algorithm look like?
GHAPPcast3 Okt 2024

FAQ: How is MASH severity staged? What would an ideal MASH NIT algorithm look like?

Thank you to Madrigal for your support of this FAQ Video Module.

In this FAQ Video Module, Jonathan Yeh, PA, from Columbia University Irving Medical Center, discusses the evolution of Metabolic Dysfunction-Associated Steatohepatitis (MASH) diagnosis and fibrosis staging. Formerly known as NASH, MASH was traditionally diagnosed through liver biopsy, but non-invasive testing (NITs) is now widely accepted for fibrosis assessment.

Key non-invasive methods include FibroScan, which uses Vibration-Controlled Transient Elastography (VCTE), the Enhanced Liver Fibrosis (ELF) Test, and the FibroSure Blood Test. When used together, these tests provide a reliable assessment of fibrosis stage, significantly reducing the need for invasive liver biopsy.

Fibrosis staging follows the METAVIR system, which categorizes fibrosis from Stage 0 (no fibrosis) to Stage 4 (cirrhosis). Additionally, necroinflammatory activity is scored from A0 to A3, representing increasing hepatitis severity. By integrating FibroScan with ELF or FibroSure blood test results, healthcare providers can improve diagnostic accuracy and ensure more effective patient management.

As non-invasive fibrosis staging continues to evolve, incorporating these advanced diagnostic tools allows for earlier detection, better disease monitoring, and improved treatment strategies for patients with MASH.

For more expert insights, visit the GHAPP website or download the GHAPP ACE app on IOS or Android.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(154)

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Mai 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Mai 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Mai 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Mai 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Mai 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...

14 Apr 18min

Populært innen Helse

fastlegen
rss-gukild-johaug
lydartikler-fra-aftenposten
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
rss-skravla-gar
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
rss-garne-damer
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-lopedrommen
hjernesterk
g-punktet
treningsprat
rss-kull
sinnsyn
hverdagspsyken